News & Updates

Show Multimedia Only

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025 by

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025 by

New research presented at EHRA 2025 has shown that patients who have taken antidepressants for extended periods are at increased risk of sudden cardiac death.

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025 by

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025

Oral as good as extended-release injectable naltrexone for hospitalized adults with AUD

11 May 2025

For hospitalized individuals initiating treatment for alcohol use disorder (AUD), oral naltrexone is equally efficacious as the extended-release injectable formulation in terms of reducing heavy drinking days, as shown in a study.

Oral as good as extended-release injectable naltrexone for hospitalized adults with AUD

11 May 2025

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

A recent study has found that dexamethasone delivers better outcomes than methotrexate (MTX) and ranibizumab in patients with persistent or recurrent uveitic macular oedema through 24 weeks. In addition, side effects are manageable.

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

09 May 2025 by

In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.